Julie Charollais-Thoenig

Publications

105

Citations

H-Index

2013

Active since

Affiliations

Institut de Chimie Organique et Analytique(Current)

École Polytechnique Fédérale de Lausanne

Université d'Orléans

Centre National de la Recherche Scientifique

University of Lausanne

Julie Charollais-Thoenig is an author at Institut de Chimie Organique et Analytique specializing in medicine, drug discovery, and lysosomal storage disease.

Top concepts

MedicineDrug DiscoveryBiochemistryGlycobiologyPharmacologyMolecular PharmacologyLysosomal Storage DiseasePathologyEngineeringSystems Biology

Publications per year

2013–2018

Publications

(5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B

Sophie Front, Anna Biela‐Banaś, Patricie Burda et al. · European Journal of Medicinal Chemistry · 2016 · 39 citations · Full text

Molecular Pharmacology, Engineering, Glycobiology +11

N‐Alkyl‐, 1‐C‐Alkyl‐, and 5‐C‐Alkyl‐1,5‐dideoxy‐1,5‐imino‐(<scp>l</scp>)‐ribitols as Galactosidase Inhibitors

Sophie Front, Estelle Gallienne, Julie Charollais-Thoenig et al. · ChemMedChem · 2015 · 30 citations

Molecular Pharmacology, Medicinal Chemistry, Protein Glycosylation +13

Effect of dark chocolate on renal tissue oxygenation as measured by BOLD-MRI in healthy volunteers

Menno Pruijm, Lucie Hofmann, Julie Charollais-Thoenig et al. · Clinical Nephrology · 2013 · 20 citations

4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations

Sophie Front, Sofia Almeida, Vincent Zoete et al. · Bioorganic & Medicinal Chemistry · 2018 · 16 citations · Full text

4-Epi-isofagomine Derivatives, Lysosomal Diseases, Biochemistry +7

Rows per page

1–4 of 4